1. Home
  2. SWAG vs TENX Comparison

SWAG vs TENX Comparison

Compare SWAG & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWAG
  • TENX
  • Stock Information
  • Founded
  • SWAG 1994
  • TENX 1967
  • Country
  • SWAG United States
  • TENX United States
  • Employees
  • SWAG N/A
  • TENX N/A
  • Industry
  • SWAG Advertising
  • TENX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SWAG Consumer Discretionary
  • TENX Health Care
  • Exchange
  • SWAG Nasdaq
  • TENX Nasdaq
  • Market Cap
  • SWAG N/A
  • TENX 21.6M
  • IPO Year
  • SWAG 2021
  • TENX N/A
  • Fundamental
  • Price
  • SWAG $1.06
  • TENX $5.82
  • Analyst Decision
  • SWAG
  • TENX Strong Buy
  • Analyst Count
  • SWAG 0
  • TENX 3
  • Target Price
  • SWAG N/A
  • TENX $16.00
  • AVG Volume (30 Days)
  • SWAG 21.1K
  • TENX 13.0K
  • Earning Date
  • SWAG 04-14-2025
  • TENX 05-20-2025
  • Dividend Yield
  • SWAG N/A
  • TENX N/A
  • EPS Growth
  • SWAG N/A
  • TENX N/A
  • EPS
  • SWAG N/A
  • TENX N/A
  • Revenue
  • SWAG $82,654,000.00
  • TENX N/A
  • Revenue This Year
  • SWAG N/A
  • TENX N/A
  • Revenue Next Year
  • SWAG N/A
  • TENX N/A
  • P/E Ratio
  • SWAG N/A
  • TENX N/A
  • Revenue Growth
  • SWAG 8.76
  • TENX N/A
  • 52 Week Low
  • SWAG $0.73
  • TENX $2.77
  • 52 Week High
  • SWAG $1.44
  • TENX $7.89
  • Technical
  • Relative Strength Index (RSI)
  • SWAG 51.28
  • TENX 52.41
  • Support Level
  • SWAG $1.00
  • TENX $5.34
  • Resistance Level
  • SWAG $1.12
  • TENX $5.87
  • Average True Range (ATR)
  • SWAG 0.07
  • TENX 0.34
  • MACD
  • SWAG -0.01
  • TENX 0.04
  • Stochastic Oscillator
  • SWAG 43.67
  • TENX 86.99

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

Share on Social Networks: